Trichostatin is a lipid of Polyketides (PK) class. Trichostatin is associated with abnormalities such as Dentatorubral-Pallidoluysian Atrophy, PARAGANGLIOMAS 3, abnormal fragmented structure, Disintegration (morphologic abnormality) and Hyperostosis, Diffuse Idiopathic Skeletal. The involved functions are known as Acetylation, Cell Differentiation process, histone modification, Gene Silencing and Transcriptional Activation. Trichostatin often locates in CD41a, Hematopoietic System, Chromatin Structure, Blood and Endothelium. The associated genes with Trichostatin are SPI1 gene, CELL Gene, Chromatin, CXCR4 gene and DNMT1 gene. The related lipids are Butyrates, Promega, butyrate, Lipopolysaccharides and Steroids. The related experimental models are Knock-out, Mouse Model, Xenograft Model and Cancer Model.
To understand associated biological information of trichostatin A, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
trichostatin A is suspected in Infection, Morphologically altered structure, Ureteral obstruction, Photosensitization, Atherosclerosis, Hypertrophic Cardiomyopathy and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with trichostatin A
Lipid pathways are not clear in current pathway databases. We organized associated pathways with trichostatin A through full-text articles, including metabolic pathways or pathways of biological mechanisms.
Pathway name | Related literatures |
---|
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Mouse Model are used in the study 'Regulation of minichromosome maintenance gene family by microRNA-1296 and genistein in prostate cancer.' (Majid S et al., 2010), Mouse Model are used in the study 'Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy.' (Fang MZ et al., 2005) and Mouse Model are used in the study 'Histone deacetylase 3 mediates allergic skin inflammation by regulating expression of MCP1 protein.' (Kim Y et al., 2012).
Xenograft Model are used in the study 'Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma.' (Landreville S et al., 2012), Xenograft Model are used in the study 'Extended treatment with physiologic concentrations of dietary phytochemicals results in altered gene expression, reduced growth, and apoptosis of cancer cells.' (Moiseeva EP et al., 2007) and Xenograft Model are used in the study 'Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model.' (Touma SE et al., 2005).
Cancer Model are used in the study 'Plasma pharmacokinetics and metabolism of the histone deacetylase inhibitor trichostatin a after intraperitoneal administration to mice.' (Sanderson L et al., 2004).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Rahman MM et al. | Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages. | 2003 | Blood | pmid:12511413 |
Zhou DC et al. | Frequent mutations in the ligand-binding domain of PML-RARalpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo. | 2002 | Blood | pmid:11830487 |
Hambach L et al. | Hypomethylating drugs convert HA-1-negative solid tumors into targets for stem cell-based immunotherapy. | 2009 | Blood | pmid:19096014 |
Petti MC et al. | Complete remission through blast cell differentiation in PLZF/RARalpha-positive acute promyelocytic leukemia: in vitro and in vivo studies. | 2002 | Blood | pmid:12130525 |
Chaurasia P et al. | Chromatin-modifying agents promote the ex vivo production of functional human erythroid progenitor cells. | 2011 | Blood | pmid:21355088 |
Wang X et al. | Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells. | 2010 | Blood | pmid:20858855 |
Witt O et al. | Induction of fetal hemoglobin expression by the histone deacetylase inhibitor apicidin. | 2003 | Blood | pmid:12393499 |
Ishiguro K and Sartorelli AC | Coinduction of embryonic and adult-type globin mRNAs by sodium butyrate and trichostatin A in two murine interleukin-3-dependent bone marrow-derived cell lines. | 1998 | Blood | pmid:9834245 |
Li X et al. | Mta3-NuRD complex is a master regulator for initiation of primitive hematopoiesis in vertebrate embryos. | 2009 | Blood | pmid:19864643 |
Menegola E et al. | Inhibition of histone deacetylase activity on specific embryonic tissues as a new mechanism for teratogenicity. | 2005 | Birth Defects Res. B Dev. Reprod. Toxicol. | pmid:16193500 |
Kalaiarasi A et al. | Copper oxide nanoparticles induce anticancer activity in A549 lung cancer cells by inhibition of histone deacetylase. | 2018 | Biotechnol. Lett. | pmid:29116558 |
Liu X et al. | The improvement of adenovirus vector production by increased expression of coxsackie adenovirus receptor. | 2009 | Biotechnol. Lett. | pmid:19330491 |
Kim HJ et al. | Enhancement of human mesenchymal stem cell differentiation by combination treatment with 5-azacytidine and trichostatin A. | 2016 | Biotechnol. Lett. | pmid:26341652 |
Seo H et al. | Modulation of immunoglobulin gene conversion in chicken DT40 by enhancing histone acetylation, and its application to antibody engineering. | 2007 | Biotechnol. Genet. Eng. Rev. | pmid:18059633 |
Tobias CA et al. | Improved recombinant retroviral titers utilizing trichostatin A. | 2000 | BioTechniques | pmid:11056820 |
Giannini G et al. | N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. | 2009 | Bioorg. Med. Chem. Lett. | pmid:19285395 |
Lee S et al. | Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors. | 2007 | Bioorg. Med. Chem. Lett. | pmid:17588744 |
Nishino N et al. | Synthesis and histone deacetylase inhibitory activity of cyclic tetrapeptides containing a retrohydroxamate as zinc ligand. | 2004 | Bioorg. Med. Chem. Lett. | pmid:15109626 |
Marson CM et al. | Stereodefined and polyunsaturated inhibitors of histone deacetylase based on (2E,4E)-5-arylpenta-2,4-dienoic acid hydroxyamides. | 2004 | Bioorg. Med. Chem. Lett. | pmid:15109636 |
Vaisburg A et al. | (2-amino-phenyl)-amides of omega-substituted alkanoic acids as new histone deacetylase inhibitors. | 2004 | Bioorg. Med. Chem. Lett. | pmid:14684344 |
Hoque MA et al. | Cyclic tetrapeptides with thioacetate tails or intramolecular disulfide bridge as potent inhibitors of histone deacetylases. | 2012 | Bioorg. Med. Chem. Lett. | pmid:23021104 |
Krennhrubec K et al. | Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors. | 2007 | Bioorg. Med. Chem. Lett. | pmid:17346959 |
Rajak H et al. | 2,5-Disubstituted-1,3,4-oxadiazoles/thiadiazole as surface recognition moiety: design and synthesis of novel hydroxamic acid based histone deacetylase inhibitors. | 2011 | Bioorg. Med. Chem. Lett. | pmid:21875796 |
Vaidya AS et al. | Novel histone deacetylase 8 ligands without a zinc chelating group: exploring an 'upside-down' binding pose. | 2012 | Bioorg. Med. Chem. Lett. | pmid:23010266 |
Loudni L et al. | Design, synthesis and biological evaluation of 1,4-benzodiazepine-2,5-dione-based HDAC inhibitors. | 2007 | Bioorg. Med. Chem. Lett. | pmid:17624773 |
Wang DF et al. | QSAR studies of PC-3 cell line inhibition activity of TSA and SAHA-like hydroxamic acids. | 2004 | Bioorg. Med. Chem. Lett. | pmid:14741273 |
Hirata Y et al. | Anti-tumor activity of new orally bioavailable 2-amino-5-(thiophen-2-yl)benzamide-series histone deacetylase inhibitors, possessing an aqueous soluble functional group as a surface recognition domain. | 2012 | Bioorg. Med. Chem. Lett. | pmid:22321215 |
Desai D et al. | SelSA, selenium analogs of SAHA as potent histone deacetylase inhibitors. | 2010 | Bioorg. Med. Chem. Lett. | pmid:20167479 |
Jose B et al. | Novel histone deacetylase inhibitors: cyclic tetrapeptide with trifluoromethyl and pentafluoroethyl ketones. | 2004 | Bioorg. Med. Chem. Lett. | pmid:15454224 |
Liao V et al. | Amide-based derivatives of β-alanine hydroxamic acid as histone deacetylase inhibitors: attenuation of potency through resonance effects. | 2012 | Bioorg. Med. Chem. Lett. | pmid:22932316 |
Pabba C et al. | Design and synthesis of aryl ether and sulfone hydroxamic acids as potent histone deacetylase (HDAC) inhibitors. | 2011 | Bioorg. Med. Chem. Lett. | pmid:21109435 |
Smil DV et al. | Novel HDAC6 isoform selective chiral small molecule histone deacetylase inhibitors. | 2009 | Bioorg. Med. Chem. Lett. | pmid:19111466 |
Islam NM et al. | Bicyclic peptides as potent inhibitors of histone deacetylases: optimization of alkyl loop length. | 2010 | Bioorg. Med. Chem. Lett. | pmid:20045316 |
Riester D et al. | Non-isotopic dual parameter competition assay suitable for high-throughput screening of histone deacetylases. | 2009 | Bioorg. Med. Chem. Lett. | pmid:19457659 |
Gupta PK et al. | Inhibitors selective for HDAC6 in enzymes and cells. | 2010 | Bioorg. Med. Chem. Lett. | pmid:20947351 |
Shinji C et al. | Design and synthesis of phthalimide-type histone deacetylase inhibitors. | 2005 | Bioorg. Med. Chem. Lett. | pmid:16137884 |
Uesato S et al. | Novel histone deacetylase inhibitors: N-hydroxycarboxamides possessing a terminal bicyclic aryl group. | 2002 | Bioorg. Med. Chem. Lett. | pmid:11992774 |
Hooven LA et al. | Effects of suberoylanilide hydroxamic acid and trichostatin A on induction of cytochrome P450 enzymes and benzo[a]pyrene DNA adduct formation in human cells. | 2005 | Bioorg. Med. Chem. Lett. | pmid:15713371 |
Chen B et al. | Chemistry and biology of mercaptoacetamides as novel histone deacetylase inhibitors. | 2005 | Bioorg. Med. Chem. Lett. | pmid:15713393 |
Yu D et al. | Clonal Rett Syndrome cell lines to test compounds for activation of wild-type MeCP2 expression. | 2011 | Bioorg. Med. Chem. Lett. | pmid:21840716 |
Vasudevan A et al. | Heterocyclic ketones as inhibitors of histone deacetylase. | 2003 | Bioorg. Med. Chem. Lett. | pmid:14592473 |
Choi E et al. | Structure and property based design, synthesis and biological evaluation of γ-lactam based HDAC inhibitors. | 2011 | Bioorg. Med. Chem. Lett. | pmid:21256006 |
Nakao Y et al. | Evaluation of antiangiogenic activity of azumamides by the in vitro vascular organization model using mouse induced pluripotent stem (iPS) cells. | 2008 | Bioorg. Med. Chem. Lett. | pmid:18397826 |
Mazitschek R et al. | Development of a fluorescence polarization based assay for histone deacetylase ligand discovery. | 2008 | Bioorg. Med. Chem. Lett. | pmid:18430569 |
Charrier C et al. | Synthesis of rigid trichostatin A analogs as HDAC inhibitors. | 2006 | Bioorg. Med. Chem. Lett. | pmid:16904890 |
Charrier C et al. | Antiproliferative activities of a library of hybrids between indanones and HDAC inhibitor SAHA and MS-275 analogues. | 2007 | Bioorg. Med. Chem. Lett. | pmid:17897824 |
Van Ommeslaeghe K et al. | Amide analogues of TSA: synthesis, binding mode analysis and HDAC inhibition. | 2003 | Bioorg. Med. Chem. Lett. | pmid:12749885 |
Suzuki T et al. | Identification of a potent and stable antiproliferative agent by the prodrug formation of a thiolate histone deacetylase inhibitor. | 2007 | Bioorg. Med. Chem. Lett. | pmid:17257837 |
Lavoie R et al. | Design and synthesis of a novel class of histone deacetylase inhibitors. | 2001 | Bioorg. Med. Chem. Lett. | pmid:11597413 |
Mukherjee P et al. | Structural insights into the Plasmodium falciparum histone deacetylase 1 (PfHDAC-1): A novel target for the development of antimalarial therapy. | 2008 | Bioorg. Med. Chem. | pmid:18362073 |